A new type of mRNA vaccine against the new coronavirus called "replicon vaccine" developed overseas was approved in Japan on the 28th. The pharmaceutical company that applied for the vaccine will develop a vaccine for the mutated virus and aim to vaccinate it in the fall or winter of next year.

The approved vaccine is a type of vaccine called "replicon vaccine" against the conventional strain of the new coronavirus, which was applied for by the pharmaceutical company "Meiji Seika Pharma".

This vaccine was developed overseas and uses a new technology in which the mRNA of the vaccinated new coronavirus is replicated in the body, so it means that the effect lasts for a long time with a small amount.

According to the company, this is the first time in the world that this type of vaccine has been approved.

In the future, the company plans to develop this type of vaccine that responds to the mutated virus and supply it for inoculation in the fall and winter of next year, and plans to proceed with manufacturing at a plant in Minamisoma City, Fukushima Prefecture.

At the press conference, Daikichiro Kobayashi, president of Meiji Seika Pharma, said, "Although it is necessary to respond to mutated viruses in the future, we believe that we have paved the way for the practical application of a new generation of vaccines ahead of the rest of the world."